Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “buy” rating restated by analysts at Jefferies Group in a research report issued to clients and investors on Friday. They currently have a GBX 1,000 ($16.76) price objective on the stock. Jefferies Group’s price objective would indicate a potential downside of 8.09% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc in a research note on Thursday. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Thursday. They now have a GBX 865 ($14.50) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Wednesday. They now have a GBX 908 ($15.22) price target on the stock. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of GBX 929.31 ($15.58).

Shares of Smith & Nephew plc (LON:SN) traded down 2.30% on Friday, hitting GBX 1063.00. 3,144,477 shares of the company’s stock traded hands. Smith & Nephew plc has a 52 week low of GBX 493.00 and a 52 week high of GBX 1136.00. The stock’s 50-day moving average is GBX 939.7 and its 200-day moving average is GBX 899.4. The company’s market cap is £9.493 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.